Medicijnen voor derde wereld voor 5 procent van de prijs'
PDF) Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
Pharmaceutical Technology Europe - August 2010 - What is Hindering the Uptake of Biosimilars
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
PDF) Challenges in standardizing safety assessments of biopharmaceuticals, the case of EPREX Associated Pure Red Cell Aplasia | Toine Pieters - Academia.edu
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
PDF) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment | Beatriz Silva Lima - Academia.edu
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
PDF) Biosimilar therapeutics—What do we need to consider?